Autopsy report · NCT00634088
Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
Cause of deathSlow enrollment
“Slow Accrual”
Life of this trial
- Registered 3 months before it started.
- Ran for about 2 years before it stopped.
- 13 participants enrolled.
- Results were posted on the registry 11 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- R-Pharm
- Sponsor type
- Industry
- Conditions
- Locally Advanced or Metastatic Breast Cancer
- Interventions
- Ixabepilone, 32 mg/m^2 + Lapatinib, 1000 mg; Ixabepilone, 32 mg/m^2 + Lapatinib, 1250 mg; Ixabepilone, 40 mg/m^2 + Lapatinib, 1250 mg; Ixabepilone + Lapatinib + Capecitabine
- Participants
- 13
- Sites
- 3
- Countries
- Australia, Italy, United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.